Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octatropine methylbromide + diazepam
- Development stage
- Phase 4
- Lead developer
- STADA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valpinax is a fixed-dose combination small molecule drug developed by Crinos S.p.A. for the treatment of irritable bowel syndrome (IBS). It consists of octatropine methylbromide, an anticholinergic agent, and diazepam, a benzodiazepine tranquilizer. Octatropine methylbromide acts as an antispasmodic by antagonizing muscarinic acetylcholine receptors in the gastrointestinal tract, thereby reducing spasms. Diazepam acts as a positive allosteric modulator of GABA-A receptors, providing anxiolytic and muscle-relaxant effects that address the psychological and neurological components often associated with IBS. The combination is typically administered orally and has been evaluated in Phase 4 clinical trials in Italy.
- Brand names
- Valpinax
- Other names
- Octatropine methylbromide and diazepam
02
Targets
GABRR (GABA-A receptor subunit rho)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on octatropine methylbromide + diazepam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octatropine methylbromide + diazepam.